1. Beta Bionics plans to pre-release Q4 2025 financial results soon. 2. Expected results include net sales and patient statistics. 3. Meetings in San Francisco will discuss these results with investors.
FAQ
Why Bullish?
Positive pre-release signals can boost investor confidence, similar to past financial announcements in the tech sector that spiked share prices. Beta Bionics’ innovations in diabetes management could drive significant market interest, as seen with previous health tech successes.
How important is it?
The upcoming earnings pre-release may influence trading behavior and market perceptions of BBNX’s future, thus affecting its valuation.
Why Short Term?
The imminent financial results will likely impact BBNX’s stock price shortly after their announcement and discussions. Previous similar events, like quarterly reports, have caused immediate price movements in biotech stocks.
IRVINE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX) (the "Company"), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to pre-release its topline fourth quarter 2025 financial results the week of January 5, 2026.
Topline financial results covered in the pre-release are expected to include net sales, new patient starts, and the percentage of new patient starts reimbursed through the pharmacy benefit plan (PBP) channel.
Members of the Company's management team will host in-person meetings in San Francisco from January 12, 2026 through January 14, 2026 to discuss topline fourth quarter 2025 results. The Company invites investors to register for in-person meetings by contacting the Company's investor relations representative at ir@betabionics.com.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com
Media and Public Relations:
Karen Hynes
Vice President of Marketing
media@betabionics.com
Source: Beta Bionics, Inc.
